Breaking News

AskBio Acquires BrainVectis

Expands clinical pipeline for neurodegenerative diseases with Huntington’s disease gene therapy candidate

By: Contract Pharma

Contract Pharma Staff

Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, has acquired BrainVectis, a Paris-based gene therapy company focused on neurodegenerative disorders, particularly, therapies that restore brain cholesterol metabolism as a treatment for Huntington’s disease and other disorders. Financial terms were not disclosed. BrainVectis was founded by Nathalie Cartier-Lacave, M.D., with funding and support from INSERM, Sorbonne University...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters